Literature DB >> 9565595

Phosphorylation of vimentin by Rho-associated kinase at a unique amino-terminal site that is specifically phosphorylated during cytokinesis.

H Goto1, H Kosako, K Tanabe, M Yanagida, M Sakurai, M Amano, K Kaibuchi, M Inagaki.   

Abstract

We found that vimentin, the most widely expressed intermediate filament protein, served as an excellent substrate for Rho-associated kinase (Rho-kinase) and that vimentin phosphorylated by Rho-kinase lost its ability to form filaments in vitro. Two amino-terminal sites on vimentin, Ser38 and Ser71, were identified as the major phosphorylation sites for Rho-kinase, and Ser71 was the most favored and unique phosphorylation site for Rho-kinase in vitro. To analyze the vimentin phosphorylation by Rho-kinase in vivo, we prepared an antibody GK71 that specifically recognizes the phosphorylation of vimentin-Ser71. Ectopic expression of constitutively active Rho-kinase in COS-7 cells induced phosphorylation of vimentin at Ser71, followed by the reorganization of vimentin filament networks. During the cell cycle, the phosphorylation of vimentin-Ser71 occurred only at the cleavage furrow in late mitotic cells but not in interphase or early mitotic cells. This cleavage furrow-specific phosphorylation of vimentin-Ser71 was observed in the various types of cells we examined. All these accumulating observations increase the possibility that Rho-kinase may have a definite role in governing regulatory processes in assembly-disassembly and turnover of vimentin filaments at the cleavage furrow during cytokinesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9565595     DOI: 10.1074/jbc.273.19.11728

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  85 in total

1.  Phospholipase D activity is required for actin stress fiber formation in fibroblasts.

Authors:  Y Kam; J H Exton
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

Review 2.  Understanding cytokinesis failure.

Authors:  Guillaume Normand; Randall W King
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 3.  Intermediate Filaments Play a Pivotal Role in Regulating Cell Architecture and Function.

Authors:  Jason Lowery; Edward R Kuczmarski; Harald Herrmann; Robert D Goldman
Journal:  J Biol Chem       Date:  2015-05-08       Impact factor: 5.157

4.  Microtubule-dependent transport of vimentin filament precursors is regulated by actin and by the concerted action of Rho- and p21-activated kinases.

Authors:  Amélie Robert; Harald Herrmann; Michael W Davidson; Vladimir I Gelfand
Journal:  FASEB J       Date:  2014-03-20       Impact factor: 5.191

Review 5.  Desmin cytoskeleton in healthy and failing heart.

Authors:  Y Capetanaki
Journal:  Heart Fail Rev       Date:  2000-10       Impact factor: 4.214

6.  Molecular diversity of rat brain proteins as revealed by proteomic analysis.

Authors:  Jae-Won Yang; Jean-François Juranville; Harald Höger; Michael Fountoulakis; Gert Lubec
Journal:  Mol Divers       Date:  2005       Impact factor: 2.943

Review 7.  The sweet side of the cell cycle.

Authors:  Ee Phie Tan; Francesca E Duncan; Chad Slawson
Journal:  Biochem Soc Trans       Date:  2017-04-15       Impact factor: 5.407

Review 8.  ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases.

Authors:  André Schmandke; Antonio Schmandke; Stephen M Strittmatter
Journal:  Neuroscientist       Date:  2007-10       Impact factor: 7.519

9.  Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.

Authors:  Saleemulla Mahammad; S N Prasanna Murthy; Alessandro Didonna; Boris Grin; Eitan Israeli; Rodolphe Perrot; Pascale Bomont; Jean-Pierre Julien; Edward Kuczmarski; Puneet Opal; Robert D Goldman
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

10.  Superoxide from NADPH oxidase upregulates type 5 phosphodiesterase in human vascular smooth muscle cells: inhibition with iloprost and NONOate.

Authors:  S Muzaffar; N Shukla; M Bond; G B Sala-Newby; A C Newby; G D Angelini; J Y Jeremy
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.